XPO1 Inhibition Using Selinexor Synergizes With Chemotherapy in Acute Myeloid Leukemia (AML) by Targeting DNA Repair and Restoring Topoisomerase IIα to the Nucleus

PURPOSE: Selinexor, a selective inhibitor of XPO1, is currently being tested as single agent in clinical trials in acute myeloid leukemia (AML). However, considering the molecular complexity of AML, it is unlikely that AML can be cured with monotherapy. Therefore we asked whether adding already esta...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Clin Cancer Res
Main Authors: Ranganathan, Parvathi, Kashyap, Trinayan, Yu, Xueyan, Meng, Xiaomei, Lai, Tzung-Huei, McNeil, Betina, Bhatnagar, Bhavana, Shacham, Sharon, Kauffman, Michael, Dorrance, Adrienne M., Blum, William, Sampath, Deepa, Landesman, Yosef, Garzon, Ramiro
Format: Artigo
Sprog:Inglês
Udgivet: 2016
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5161584/
https://ncbi.nlm.nih.gov/pubmed/27358488
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-15-2885
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker